- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00447187
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
A Multi-center, Placebo-Controlled, Randomized, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure Following Penetrating Keratoplasty With LX201 Implantation in Subjects Who Are at Increased Immunological Risk
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was intended for surgical episcleral placement in the eye.
The study was a Phase 2/3, multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study of LX201 for prevention of corneal allograft rejection or graft failure following penetrating keratoplasty with LX201 implantation. Subjects were to be followed in an outpatient setting for safety and efficacy at 4-6 week intervals for 52 weeks following transplantation surgery.
After Visit 12 (Week 52), subjects in the USA and India with the implant in the study eye were to be followed for safety at least once per year for a 2-year period or until time of implant removal. For subjects in the USA and India, if the implant was removed at any time prior to the 3 year safety follow-up, the subject was to have a final safety follow up visit at 3 months post removal. In Germany, the implant was to be removed at Week 52 with a 3-month safety follow-up period after removal.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Erlangen, Duitsland, 91054
- Augenklinik, Universitat Erlangen-Nurnberg
-
Essen, Duitsland, 45122
- Cornea Bank, Universitätsklinikum Essen
-
Kiel, Duitsland, 24105
- Klinik fuer Ophthalmologie Campus Kiel
-
Muenchen, Duitsland, 80336
- Ludwig Maximilians Universität
-
München, Duitsland, 81675
- Augenklinik der Technischen Universität München
-
Wuerzburg, Duitsland, 97080
- Augenklinik Wuerzburg
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85032
- Cornea Consultants of Arizona
-
-
California
-
Loma Linda, California, Verenigde Staten, 92354
- Loma Linda University Health Care
-
Los Angeles, California, Verenigde Staten, 90033
- USC Doheny Eye Institute
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33136
- Bascom Palmer Eye Institute
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Emory Eye Center
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- University of Illinois at Chicago
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46260
- Price Vision Group
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21218
- The Eye Center at Union Memorial Hospital
-
Baltimore, Maryland, Verenigde Staten, 21287
- Wilmer Eye Institute, Cornea Service
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02111
- New England Eye Center
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48105
- W.K. Kellogg Eye Center - University of Michigan
-
-
Minnesota
-
Bloomington, Minnesota, Verenigde Staten, 55431
- MN Eye Consultants, P.A.
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64111
- Tauber Eye Center
-
St. Louis, Missouri, Verenigde Staten, 63141
- Ophthalmology Associates
-
-
New Jersey
-
Newark, New Jersey, Verenigde Staten, 07103
- UMDNJ - New Jersey Medical School Institute of Ophthalmology and Visual Science
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Mount Sinai School of Medicine
-
New York, New York, Verenigde Staten, 10003
- New York Eye and Ear Infirmary
-
Rockville Center, New York, Verenigde Staten, 11570
- Ophthalmic Consultants of Long Island
-
Slingerlands, New York, Verenigde Staten, 12159
- Cornea Consultants of Albany
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27705
- Duke University Eye Center
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- University Hospitals Case Medical Center
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75231
- Cornea Associates of Texas
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten, 23502
- Virginia Eye Consultants
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98104
- Eye Associates NW
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Subjects are candidates for a corneal transplant and are at increased immunological risk for graft failure, as evidenced by one or more of the following:
- ≥ 1 quadrant deep corneal vascularization
- verifiable history of graft failure due to rejection
- position of graft is < 1 mm from the limbus
Exclusion Criteria:
- Any condition that would greatly increase the risk of non-rejection graft failure such as Stevens-Johnson syndrome, xerophthalmia or severe exposure keratitis.
- Schirmer's test ≤ 5 mm in 1 minute
- Clinical evidence of limbal stem cell deficiency
- History of or active herpes simplex virus keratitis or other acute corneal infection
- Subjects who have had > 3 failed grafts in the study eye
- Uncontrolled glaucoma as evidenced by an intraocular pressure of >21 mmHg while on maximal medical therapy
- Clinically suspected or confirmed ocular lymphoma
- Treatment with a systemic immunosuppressive regimen within the previous 30 days; systemic prednisone (or its equivalent) of ≤ 10 mg daily is, however, permitted.
- Any implantable corticosteroid-eluting device (e.g., Retisert™, Posurdex®, Medidur™, I-vation™ TA intravitreal implant)
- Subjects who periodically require high-dose systemic steroid treatment (e.g., for exacerbation of chronic obstructive pulmonary disease).
- Subjects who have received treatment with a monoclonal antibody or any other biologic therapy within the previous 90 days or alemtuzumab within the previous 12 months
- History of herpes zoster or varicella infection within 6 weeks prior to enrollment, or chicken pox exposure within 21 days before enrollment
- Seropositivity for human immunodeficiency virus (HIV)
- Previous exposure or known contraindication to administration of cyclosporine
- Recipients of a solid organ transplant
- Currently pregnant or lactating
- Active, extraocular and/or systemic infection requiring the prolonged or chronic use of antimicrobial agents or the presence of active hepatitis A, B or C
- Severe anemia (hemoglobin < 6 g/dL), leukopenia (white blood cell count [WBC] < 2500 mm3), thrombocytopenia (platelet count < 80,000 mm3), polycythemia (hematocrit [Hct] > 54% [male] or Hct > 49% [female]) or clinically significant coagulopathy
- Current malignancy or a history of malignancy (within the previous 5 years) except non-metastatic basal or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix that has been treated successfully
- Active peptic ulcer disease
- Co-morbid conditions that require immunosuppression
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: LX201 0,50 inch implantaat
LX201-implantaat bevatte 30% cyclosporine A in gewicht en 0,50 inch lang
|
LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded. |
Experimenteel: LX201 0,75 inch implantaat
Het LX201-implantaat bevatte 30% cyclosporine A in gewicht en 0,75 inch in lengte
|
LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded. |
Placebo-vergelijker: Placebo-implantaat van 0,75 inch
Siliconenimplantaat zonder cyclosporine A, 0,75 inch lang
|
De placebo was een siliconenimplantaat van 0,75 inch lang.
Het bevatte geen ciclosporine A
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
graft rejection or graft failure
Tijdsspanne: 52 weeks
|
52 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Eddy Anglade, MD, Chief Medical Officer, Lux Biosciences, Inc.
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- LX201-01
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Corneale ziekten
-
University of PennsylvaniaVoltooidPatiënten met primaire of secundaire diagnose Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Behalve wanneer het 5e cijfer 2 was)Verenigde Staten
-
SpringWorks Therapeutics, Inc.VerkrijgbaarNeurofibromatose Type 1-geassocieerde plexiforme neurofibromen | Histiocytisch neoplasma | Andere MAP-K Pathway Driven Diseases
Klinische onderzoeken op LX201
-
Lux Biosciences, Inc.BeëindigdHoornvliestransplantatie | Afwijzing van hoornvliestransplantaatVerenigde Staten, Duitsland